Swiss-based biotech QGel is hoping to offer a novel approach to precision medicine by solving several of the current challenges with ‘organoids’, which can be used to test medicines on organ-like tissue cultures.
23 Apr 2019
Lausanne

Swiss-based biotech QGel is hoping to offer a novel approach to precision medicine by solving several of the current challenges with ‘organoids’, which can be used to test medicines on organ-like tissue cultures. Founder and CEO Dr Colin Sanctuary tells us more.

The vital job of precision medicine is to match the right drugs to the right patients. In cancer precision medicine, this generally means to identify the treatment that will best decrease the tumor size or even eradicate the patient’s cancer.

But there are still critics that put the entire concept of precision medicine into question. My view is that Next-Generation Genetic Sequencing (NGS) for precision medicine, as fantastic as it is, still largely relies on… Continue Article Here:

Back to News and Media